Evommune Inc. announced it has entered into a definitive, worldwide license agreement with AprilBio Co. Ltd. for an IL-18 targeted fusion protein. Under the terms of the agreement, Evommune receives exclusive, worldwide rights to research, develop and commercialize APB-R3, to now be known as EVO301, a long-acting injectable fusion protein that is designed to neutralize the signal pathway of IL-18 for the regulation of inflammation.

Evommune plans to initiate a Phase 2 clinical trial in early 2025.